A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.0 个研究点目标入组 870 人开始时间: 2020年4月10日最近更新: 2020年8月18日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
入组人数: 870

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Has pathologically (histologically or cytologically) confirmed NSCLC.
•2. Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8.
•3. Is unable to undergo surgery with curative intent for Stage III NSCLC as documented by a multidisciplinary tumor board or by the treating physician in consultation with a thoracic surgeon.
•4. Has no evidence of metastatic disease, indicating Stage IV NSCLC, in whole-body fluorodeoxyglucose (FDG)-PET or FDG-PET/CT and CT or MRI scans of diagnostic quality of chest, abdomen, pelvis and brain.
•5. Has measurable disease as defined by RECIST 1.1, with at least one lesion being appropriate for selection as a target lesion, as determined by local site investigator/radiology review.
•6. Has not received prior treatment (chemotherapy, targeted therapy or radiotherapy) for their Stage III NSCLC.
•7. Has provided tumor tissue sample (tissue biopsy [core, incisional, or excisional]). FFPE blocks are preferred to slides. Newly obtained tumor sample is highly preferred over archival tissue and should be obtained prior to the thoracic imaging at screening.
•8. Has a performance status of 0 or 1 on the ECOG Performance Status assessed within 7 days prior to the first administration of study intervention.
•9. Has a life expectancy of at least 6 months.
•10. Has adequate PFT defined as a FEV1 >50% of predicted normal volume and the carbon monoxide lung diffusing capacity (DLCO) >40% of predicted normal value. Participants for whom DLCO measurements are not available will be deemed to have adequate oxygen transfer if pulse oximetry (O2 saturation) is determined to be =90% on room air.
•11. Has adequate organ function; ; all screening laboratory tests
•should be performed within 10 days prior to initiation of study intervention.
•12. Is male or female of at least 18 years to 120 years of age inclusive, at the time of signing the informed consent.
•13. A male participant must agree to use contraception as detailed in Appendix 4 of this protocol during the treatment period and for at least 180 days following the last dose of study intervention.
•14. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
•a. Not a WOCBP
•b. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 180 days following the last dose of study intervention.
•15. Has (or legally acceptable representative if applicable) provided written informed consent/assent for the study. The participant may also provide consent/assent for future biomedical research. However, the participant may participate in the main trial without participating in future biomedical research.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 460
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 410

排除标准

•1. Has small cell lung cancer or a mixed tumor with presence of small cell elements.
•2. Has history, current diagnosis, or features suggestive of MDS/AML.
•3. Has had documented weight loss >10% (from baseline) in the preceding 3 months.
•4. Has a radiation treatment plan that is likely to encompass a volume of whole lung (total lung V20-GTV) receiving > 20 Gy in total (V20) of more than 34% of lung volume.
•5. Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus,mediastinum, or for breast cancer.
•6. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX- 40, CD137).
•7. Has received prior therapy with olaparib or with any other PARP inhibitor.
•8. Had major surgery <4 weeks prior to the first dose of study medication (except for placement of vascular access).
•9. Is expected to require any other form of antineoplastic therapy, while on study.
•10. Has received a live vaccine within 30 days prior to the first dose of study medication.
•11. Has received colony-stimulating factors within 28 days prior to the first dose of study intervention.
•12. Is currently receiving either strong or moderate inducers of CYP3A4 that cannot be discontinued for the duration of the study. The required washout period prior to starting olaparib is 5 weeks for pentobarbital and 3 weeks for other agents.
•13. Is currently receiving either strong or moderate inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study. The required washout period prior to starting olaparib is 2 weeks.
•14. Pemetrexed-specific: Is unable to interrupt aspirin or other NSAIDs, other than an aspirin dose =1.3 grams per day, for at least 2 days (5 days for long-acting agents [for example, piroxicam]) before, during, and for at least 2 days after administration of pemetrexed.
•15. Pemetrexed-specific: Is unable/unwilling to take folic acid, vitamin B12, and dexamethasone.
•16. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
•17. Has resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator or participant has congenital long QT syndrome.
•18. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication.
•19. Has a known additional malignancy that is progressing or has required active treatment within the past 5 years.
•20. Has severe hypersensitivity (= Grade 3) to study intervention and/or any of its excipients
•21. Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
•22. Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. Lymphangitic spread of the NSCLC is not exclusionary.
•23. Has an active infection requiri

研究者

发起方

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

相似试验

进行中（未招募）

1 期

Phase 3 Study of Pembrolizumab with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib compared to Concurrent Chemoradiation Therapy Followed by Durvalumab in Stage III NSCLCunresectable, locally advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-003237-41-EEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.870

进行中（未招募）

1 期

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)on-small cell lung cancerMedDRA version: 21.1Level: LLTClassification code: 10029514Term: Non-small cell lung cancer NOS Class: 10029104

CTIS2023-503591-25-00Merck Sharp & Dohme LLC944

进行中（未招募）

1 期

EUCTR2019-003237-41-DEMerck Sharp & Dohme LLC870

进行中（未招募）

1 期

EUCTR2019-003237-41-LTMerck Sharp & Dohme LLC870

进行中（未招募）

1 期

EUCTR2019-003237-41-LVMerck Sharp & Dohme LLC870